Dyslipidemia in Type 2 Diabetes
Information source: Merck
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Diabetes Mellitus, Type II; Dyslipidemia
Intervention: MK0767 (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Merck Official(s) and/or principal investigator(s):
Medical Monitor, Study Director, Affiliation: Merck
Summary
The purpose of the study is to compare the lipid-altering effects of MK0767, glipizide, and
pioglitazone after 12 weeks of treatment.
This is an early phase trial and some specific protocol information is in progress and not
publicly available at this time. (Full information is available to trial participants).
Clinical Details
Study design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Eligibility
Minimum age: 21 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Men and non-pregnant females
- Age greater than or equal to 21 years
- Stop current diabetes therapy (if applicable)
- Stop current statin therapy (if applicable)
Exclusion Criteria:
- History of type 1 diabetes mellitus or ketoacidosis who are currently being treated
with insulin
- Patients on a weight loss program with ongoing weight loss, or starting an intensive
exercise program within the last four weeks
- Patients requiring treatment with corticosteroids for more than 14 consecutive days
- Patients taking warfarin or warfarin-like anti-coagulants
- Patients undergoing surgery within 30 days of Visit 1
- Patients with Hepatitis B, Hepatitis C, active liver or gallbladder disease
- Patients with history of pancreatitis or uncontrolled high blood pressure
Locations and Contacts
Additional Information
Starting date: May 2003
Ending date: May 2004
Last updated: October 19, 2007
|
